Current
40.0×
5-Year Average
38.5×
All-Time High
89.3×
All-Time Low
12.8×
P/FCF Ratio daily chart for Novo Nordisk (NVO)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/FCF Ratio for Novo Nordisk (NVO) from 2004 to 2025
| 2025 | $226.31B | $4.30B | 52.6× | +14.9× | |
| 2024 | $383.10B | $10.16B | 37.7× | -7.0× | |
| 2023 | $455.77B | $10.19B | 44.7× | +12.1× | |
| 2022 | $305.06B | $9.35B | 32.6× | -0.5× | |
| 2021 | $256.12B | $7.73B | 33.1× | +6.9× | |
| 2020 | $162.15B | $6.18B | 26.2× | +1.3× | |
| 2019 | $136.69B | $5.49B | 24.9× | +3.2× | |
| 2018 | $111.37B | $5.13B | 21.7× | -5.6× | |
| 2017 | $133.70B | $4.90B | 27.3× | +12.2× | |
| 2016 | $90.10B | $5.97B | 15.1× | -16.4× | |
| 2015 | $149.17B | $4.74B | 31.5× | +8.7× | |
| 2014 | $110.79B | $4.87B | 22.8× | -2.1× | |
| 2013 | $98.35B | $3.96B | 24.8× | -3.0× | |
| 2012 | $89.07B | $3.20B | 27.8× | +8.6× | |
| 2011 | $65.08B | $3.38B | 19.2× | -3.9× | |
| 2010 | $64.87B | $2.80B | 23.1× | +6.7× | |
| 2009 | $37.92B | $2.30B | 16.5× | +1.7× | |
| 2008 | $31.66B | $2.15B | 14.8× | -14.7× | |
| 2007 | $40.98B | $1.39B | 29.4× | -6.9× | |
| 2006 | $26.80B | $737.92M | 36.3× | +13.3× | |
| 2005 | $18.37B | $796.93M | 23.0× | -1.3× | |
| 2004 | $18.19B | $746.58M | 24.4× | — |
- 202552.6×
- 202437.7×
- 202344.7×
- 202232.6×
- 202133.1×
- 202026.2×
- 201924.9×
- 201821.7×
- 201727.3×
- 201615.1×
- 201531.5×
- 201422.8×
- 201324.8×
- 201227.8×
- 201119.2×
- 201023.1×
- 200916.5×
- 200814.8×
- 200729.4×
- 200636.3×
- 200523.0×
- 200424.4×
About P/FCF Ratio at Novo Nordisk (NVO)
Novo Nordisk (NVO) P/FCF ratio is 40.0× as of June 5, 2026. The 5-year average is 38.5×. The sector median currently stands at 19.8×. The current ratio is at the 72th percentile of its own 10-year history.
Novo Nordisk (NVO) historical P/FCF ratio has ranged from a low of 12.8× (2009) to a high of 89.3× (2024) in the available daily series.
The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.
Novo Nordisk P/FCF Ratio by Year
Novo Nordisk P/FCF Ratio 2025: 52.6×
Novo Nordisk (NVO) P/FCF ratio in 2025 was 52.6×, expanded from 37.7× the prior year.
Novo Nordisk P/FCF Ratio 2024: 37.7×
Novo Nordisk (NVO) P/FCF ratio in 2024 was 37.7×, contracted from 44.7× the prior year.
Novo Nordisk P/FCF Ratio 2023: 44.7×
Novo Nordisk (NVO) P/FCF ratio in 2023 was 44.7×, expanded from 32.6× the prior year.
Novo Nordisk P/FCF Ratio 2022: 32.6×
Novo Nordisk (NVO) P/FCF ratio in 2022 was 32.6×, contracted from 33.1× the prior year.
Novo Nordisk P/FCF Ratio 2021: 33.1×
Novo Nordisk (NVO) P/FCF ratio in 2021 was 33.1×.
Sector peers by P/FCF Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/FCF Ratio — table
Healthcare peers of Novo Nordisk (NVO), ranked by P/FCF ratio.
| 17.8× | |
| 17.8× | |
| 16.9× | |
| 16.9× | |
| 16.7× | |
| 16.4× | |
| 16.3× | |
| 15.9× | |
| 14.0× | |
| 13.5× | |
| 12.9× | |
| 12.5× | |
| 12.4× | |
| 12.2× | |
| 12.1× | |
| 11.3× | |
| 10.7× | |
| 10.4× | |
| 10.3× | |
| 10.0× | |
| 9.6× | |
| 9.1× | |
| 9.1× | |
| 6.9× | |
| 2.5× |
- 17.8×
- 16.9×
- 16.7×
- 16.4×
- 13.5×
- 12.9×
- 12.4×
- 10.7×
- 10.3×
- 9.1×
- 9.1×
- 6.9×
- 2.5×
Frequently asked questions
Novo Nordisk (NVO) Key Financials
Charts, filings, and peer comparison for every metric